Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saroglitazar - Zydus Cadila

Drug Profile

Saroglitazar - Zydus Cadila

Alternative Names: [14C] saroglitazar; [14C]-Saroglitazar; Lipaglyn; Saroglitazar Magnesium; Saroglitazar Mg; ZY-H1

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zydus-Cadila
  • Developer Zydus Cadila; Zydus Discovery DMCC
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypertriglyceridaemia
  • Phase III Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Type 2 diabetes mellitus
  • Phase II Polycystic ovary syndrome

Most Recent Events

  • 03 Oct 2019 Efficacy data from a phase II EVIDENCES-IV trial in Non-Alcoholic Steatohepatitis (NASH) released by Zydus Cadila
  • 20 Sep 2019 Zydus Discovery initiates enrolment in a phase I trial (In volunteers) in USA (NCT04112446)
  • 19 Aug 2019 Phase-I clinical trials in Dyslipidaemias (In volunteers) in India (PO) (NCT04045769)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top